Reardon, Sara (2023) Alzheimer’s drug donanemab helps most when taken at earliest disease stage, study finds. Nature, 619 (7971) Springer Science and Business Media LLC. 682-683 doi:10.1038/d41586-023-02321-1
| Reference Type | Journal (article/letter/editorial) | ||
|---|---|---|---|
| Title | Alzheimer’s drug donanemab helps most when taken at earliest disease stage, study finds | ||
| Journal | Nature | ||
| Authors | Reardon, Sara | Author | |
| Year | 2023 (July 27) | Volume | 619 |
| Issue | 7971 | ||
| Publisher | Springer Science and Business Media LLC | ||
| DOI | doi:10.1038/d41586-023-02321-1Search in ResearchGate | ||
| Generate Citation Formats | |||
| Mindat Ref. ID | 16623939 | Long-form Identifier | mindat:1:5:16623939:3 |
| GUID | 0 | ||
| Full Reference | Reardon, Sara (2023) Alzheimer’s drug donanemab helps most when taken at earliest disease stage, study finds. Nature, 619 (7971) Springer Science and Business Media LLC. 682-683 doi:10.1038/d41586-023-02321-1 | ||
| Plain Text | Reardon, Sara (2023) Alzheimer’s drug donanemab helps most when taken at earliest disease stage, study finds. Nature, 619 (7971) Springer Science and Business Media LLC. 682-683 doi:10.1038/d41586-023-02321-1 | ||
| In | (2023, July) Nature Vol. 619 (7971) Springer Science and Business Media LLC | ||
See Also
These are possibly similar items as determined by title/reference text matching only.
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|